Last reviewed · How we verify

Gavreto — Competitive Intelligence Brief

Gavreto (PRALSETINIB) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Kinase Inhibitor [EPC]. Area: Oncology.

marketed Kinase Inhibitor [EPC] RET Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Gavreto (PRALSETINIB) — Rigel Pharms. Pralsetinib inhibits RET kinase and its oncogenic fusions/mutations, blocking downstream signaling and reducing tumor growth.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Gavreto TARGET PRALSETINIB Rigel Pharms marketed Kinase Inhibitor [EPC] RET 2020-01-01
Sohonos PALOVAROTENE Ipsen marketed Retinoid [EPC] Retinoic acid receptor gamma 2023-01-01
Amvuttra VUTRISIRAN Alnylam Pharmaceuticals marketed Small Interfering RNA transthyretin (TTR) mRNA 2022-01-01
Retevmo SELPERCATINIB Eli Lilly marketed Kinase Inhibitor [EPC] Proto-oncogene tyrosine-protein kinase receptor Ret 2020-01-01
Vyndaqel tafamidis-test Foldrx Pharms marketed tafamidis Transthyretin 2019-01-01
Vyndaqel tafamidis Foldrx Pharms marketed tafamidis Transthyretin 2019-01-01
Vyndaqel Tafamidis Foldrx Pharms marketed tafamidis Transthyretin 2019-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

Sponsor landscape (Kinase Inhibitor [EPC] class)

  1. · 12 drugs in this class
  2. Pfizer · 7 drugs in this class
  3. Novartis · 3 drugs in this class
  4. Bayer · 2 drugs in this class
  5. Boehringer Ingelheim · 2 drugs in this class
  6. AstraZeneca · 2 drugs in this class
  7. Beigene Usa Inc · 1 drug in this class
  8. BeiGene · 1 drug in this class
  9. AbbVie · 1 drug in this class
  10. Bristol · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Gavreto — Competitive Intelligence Brief. https://druglandscape.com/ci/pralsetinib. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: